challenges and opportunities of digital therapeutics in the EU

Digital therapeutics which could help transform patient care ... - EFPIA

... benefits to healthcare systems, according to a new report out today by the European Federation of Pharmaceutical Industries and Associations ...

6 Digital Therapeutics Challenges & How to Overcome Them

Despite the many potential benefits of this treatment option, there are still adoption challenges faced by digital therapeutics companies.

9 Challenges and Opportunities in DTx Adoption - Sidekick Health

The Opportunity: There are opportunities for digital therapeutic companies including choosing public markets (UK NHS or US Medicaid) ...

How can digital therapeutics help Europe? - Sitra

Europe currently does not work as a single market nor is there mutual recognition of certification or in many cases even clinical evidence.

Opportunities and Challenges for Decentralized Clinical Trials

Key challenges recognized by regulators for DCTs include concerns regarding investigator oversight and participants' safety when physical examinations and face‐ ...

Digital Therapeutics: Past Trends and Future Prospects - Evidera

Advances in and the increasingly dominant role of mobile technology and artificial intelligence (AI) in our everyday lives have broadened the role of DTx in ...

Advancing Access to Digital Therapeutics in Europe - LinkedIn

However, the widespread adoption of DTx across Europe faces several challenges, including regulatory discrepancies, inadequate value assessment ...

Europe Digital Therapeutics (Dtx) Market Size & Potential By 2031

Europe Digital Therapeutics (DTx) Market was USD 699.24 million in 2023 and will reach a value of USD 3488.44 million, growing with a CAGR of 23.4% by 2031.

Towards harmonised EU Landscape for Digital Health:

New opportunities for digital health have begun in ... requirements for DTx in the EU to create a single digital therapeutics market.

Challenges Faced by Digital Therapeutics Developers

Adoption of DTx can be a multi-front battle. From the patient perspective, interest in the technology may wane if outcomes are not immediate.

Exploring the potential of digital therapeutics

DTx are covered by EU regulation 2017/745 on medical devices, which came into force in May 2021. The EU Medical Device Regulation contains no ...

Digital therapeutics from bench to bedside | npj Digital Medicine

As a new therapeutic technique based on digital technology, the commercialization and clinical application of digital therapeutics (DTx) are ...

Advancing DTx - Digital Therapeutics Alliance

Establishing the formal definition of a digital therapeutic and core principles to which all DTx products must adhere · Enabling clinicians and decision makers ...

Digital Therapeutics (DTx): how to get reimbursed in the EU, UK and ...

Digital therapeutics (DTx) are a growing trend in the EU and worldwide. It offers considerable opportunities for companies to deliver ...

HOW CAN DIGITAL THERAPEUTICS HELP EUROPE? | Sitra

The opportunity presented by this field cannot be overstated or missed. Challenges of DTx. Why have DTx not become a staple of healthcare? Why.

Digital Therapeutics (DTx) | Business & Information Systems ...

New regulatory frameworks were introduced in the United States, Asia, and several European countries. With those, DTx are becoming a new pillar ...

Germany's digital health changes - Deep Dive - Pharmaphorum

Digital therapeutics are gaining momentum and offer developers both a huge opportunity and a stimulating market access challenge.

Digital therapeutics: An exciting innovation, but not without challenges

The challenges are identifying key opportunities; carving out distinct value propositions; accessing a broader patient population and the market ...

Understanding DTx - Digital Therapeutics Alliance

Addressing Challenges in Global Healthcare · Delivering therapies using smartphones, tablets, and similar technologies · Increasing patient access to clinically ...

Access and reimbursement pathways for digital health solutions and ...

However, there are still challenges regarding reimbursement opportunities that limit scalability, given that regulatory frameworks differ among ...